HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2448-2457

  Konecny, Gottfried ^a   Untch, Michael ^b   Arboleda, Jane ^a   Wilson, Cindy ^a   Kahlert, Stephen ^b   Boettcher, Berit ^b   Felber, Margrit ^b   Beryt, Malgorzota ^a   Lude, Sandra ^b   Hepp, Hermann ^b   Slamon, Dennis ^a   Pegram, Mark ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CORRELATION FUNCTION; DISEASE ASSOCIATION; EVALUATION; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR, ERBB-2; RETROVIRIDAE; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034886716     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. The type I growth factor receptors in human breast cancer
2. Human breast cancer: Correlation of relapse and survival with amplification on HER-2/neu oncogene
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
5. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
6. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
7. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): Increased invasiveness may contribute to poor prognosis
8. ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells
9. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase
10. Heregulin induced cell invasion of HER-2/neu transfected breast cancer cell line is mediated through activation of the phosphatidylinositol 3-kinase/AKT2 pathway
11. Correlates of urokinase-type plasminogen activator in colorectal cancer: Positive relationship with nm23 and c-erbB-2 protein expression
12. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems
13. Plasminogen activators, tissue degradation, and cancer
14. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
15. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression
16. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
17. Urokinase-type plasminogen activator antigen and early relapse in breast cancer
18. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients
19. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
20. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
21. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
22. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer
23. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma
24. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum based chemotherapy
25. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
26. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer
27. Transforming mediated by the human HER-2 gene independent of the epidermal growth factor receptor
28. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
29. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
30. Sensitivity of HER-/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
31. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
32. Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies
33. Nonparametric estimation from incomplete observations
34. HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
35. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
36. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs. benign breast tumours
37. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
38. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
39. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
40. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
41. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon
42. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer
43. c-erbB-2 oncogene product expression and prognosis in gastric carcinoma
44. Amplification of the c-erbB-2 gene in gastric carcinoma: Correlation with survival
45. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
46. The urokinase-type plasminogen activator system in cancer metastasis: A review
47. Immunohistochemical expression of uPA, UPAR, and PAI in breast cancer: Fibroblastic expression has a strong association with tumor pathology
48. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis
49. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients
50. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
51. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene
52. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells
53. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells
54. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer